Cosmos Health Announces Contract Manufacturing Pipeline Exceeds $20 Million
What happened
Cosmos Health Inc. announced that the contract manufacturing (CMO) pipeline of its wholly owned subsidiary, Cana Laboratories S.A., has surpassed $20 million in implied revenue. This pipeline represents over $18 million in implied gross profit across the life of agreements, with gross margins averaging over 90%. The production pipeline currently exceeds 32.7 million units, showing growth of approximately sixfold since mid-2024.
From pr-inside.com
Why it matters
The contract manufacturing business is a key driver for the company, supporting the 2029 guidance targets of $200.6 million in revenue and $71.2 million in gross profit. The business is diversified across 11 therapeutic categories, with contracts averaging approximately four years and some extending up to ten years.
From pr-inside.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- CMOSpeculative
Cosmos Health Inc. could see its revenue targets supported by the high-margin contract manufacturing division.